Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956317 | 0.79 | CCR1 (0.48) | CCR1CCR8NOS3NOS2RAB9A | |
| SCHEMBL29955389 | 0.79 | CCR1 (0.48) | CCR1CCR8NOS3NOS2RAB9A | |
| SCHEMBL1846388 | 0.69 | GRM5 (0.43) | CCR1CCR8NOS3NOS2RAB9A | |
| SCHEMBL9611 | 0.67 | — | — | |
| SCHEMBL30421349 | 0.67 | — | — | |
| SCHEMBL1771685 | 0.67 | CCR1 (0.71) | CCR1CCR8NOS3NOS2RAB9A | |
| SCHEMBL31189737 | 0.65 | CCR1 (0.43) | CCR1CCR8NOS3NOS2RAB9A | |
| Cyanide SCHEMBL27966830 | 0.65 | CCR1 (0.60) | CCR1CCR8NOS3NOS2RAB9A | |
| Bromide SCHEMBL5437785 | 0.64 | — | — | |
| Iodide SCHEMBL8148528 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134683-A1 | HETEROCYLCIC COMPOUNDS AS IDH2 INHIBITORS | TELIGENE LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134683-A1 | HETEROCYLCIC COMPOUNDS AS IDH2 INHIBITORS | IDH2, IDH1, IDH3A | CCR1 3859/4885CCR8 4033/4885NOS3 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.